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Abstract: Background Recent studies have reported the additive value of combined gallium 68 (Ga)-
labeled Glu-urea-Lys (Ahx)-HBED-CC ligand targeting the prostate-specific membrane antigen (PSMA)
(hereafter called Ga-PSMA-11) PET/MRI for the detection and localization of primary prostate cancer
compared with multiparametric MRI. Purpose To compare the diagnostic accuracy and interrater agree-
ment of multiparametric MRI and Ga-PSMA-11 PET/MRI for the detection of extracapsular extension
(ECE) and seminal vesicle infiltration (SVI) in patients with prostate cancer. Materials and Methods
Retrospective analysis of 40 consecutive men who underwent multiparametric MRI and Ga-PSMA-11
PET/MRI within 6 months for suspected prostate cancer followed by radical prostatectomy between
April 2016 and July 2018. Four readers blinded to clinical and histopathologic findings rated the prob-
ability of ECE and SVI at multiparametric MRI and PET/MRI by using a five-point Likert-type scale.
The prostatectomy specimen served as the reference standard. Accuracy was assessed with a multireader
multicase analysis and by calculating reader-average areas under the receiver operating characteristics
curve (AUCs), sensitivity, and specificity for ordinal and dichotomized data in a region-specific and
patient-specific approach. Interrater agreement was assessed with the Fleiss multirater ฀. Results For
multiparametric MRI versus PET/MRI in ECE detection, respectively, AUC, sensitivity, and specificity
in the region-specific analysis were 0.67 and 0.75 ( .07), 28% (21 of 76) and 47% (36 of 76) ( .09), and
94% (529 of 564) and 90% (509 of 564) ( .007). For the patient-specific analysis, AUC, sensitivity, and
specificity were 0.66 and 0.73 ( .19), 46% (22 of 48) and 69% (33 of 48) ( .04), and 75% (84 of 112)
and 67% (75 of 112) ( .19), respectively. For multiparametric MRI versus PET/MRI in SVI detection,
respectively, AUC, sensitivity, and specificity of the region-specific analysis were 0.66 and 0.74 ( .21),
35% (seven of 20) and 50% (10 of 20) ( .25), and 98% (295 of 300) and 94% (282 of 300) ( < .001). For
the patient-specific analysis, AUC, sensitivity, and specificity were 0.65 and 0.79 ( .25), 35% (seven of
20) and 55% (11 of 20) ( .20), and 98% (137 of 140) and 94% (131 of 140) ( .07), respectively. Interrater
reliability for multiparametric MRI versus PET/MRI did not differ for ECE (฀, 0.46 vs 0.40; = .24)
and SVI (฀, 0.23 vs 0.33; = .39). Conclusion Our results suggest that gallium 68 (Ga)-labeled Glu-urea-
Lys (Ahx)-HBED-CC ligand targeting the prostate-specific membrane antigen (PSMA) (Ga-PSMA-11)
PET/MRI and multiparametric MRI perform similarly for local staging of prostate cancer in patients
with intermediate-to-high-risk prostate cancer. The increased sensitivity of Ga-PSMA-11 PET/MRI for
the detection of extracapsular disease comes at the cost of a slightly reduced specificity. © RSNA, 2019.
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I
n patients with prostate cancer, the detection of extracap-
sular extension (ECE) and seminal vesicle invasion (SVI) 
is not only important for selecting the appropriate therapy 
but also for preoperative planning of the surgical strategy 
and for patient prognosis (1,2). The presence of ECE has 
surgical consequences for pericapsular structures, especially 
for the neurovascular bundles. Current guidelines recom-
mend performing nerve-sparing radical prostatectomy 
(RP) in cases of localized disease (3). A high risk of ad-
vanced disease, by contrast, is in general a contraindication 
to nerve-sparing RP (3).
To predict the risk of advanced disease, clinicians often 
use staging nomograms. While earlier nomograms did not 
include medical imaging information, recent research has 
demonstrated an improved accuracy in predicting ECE by 
incorporating information from multiparametric MRI (4). 
Multiparametric MRI is a well-established imaging modality 
in prostate cancer assessment, particularly for depicting clin-
ically significant prostate cancer and improving the yield of 
transrectal US–guided biopsy (5–8). Moreover, it has been 
reported to be useful for local staging (9,10) and to have 
potential to assess prostate cancer aggressiveness (11).
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Background: Recent studies have reported the additive value of combined gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC 
ligand targeting the prostate-specific membrane antigen (PSMA) (hereafter called 68Ga-PSMA-11) PET/MRI for the detection and 
localization of primary prostate cancer compared with multiparametric MRI.
Purpose: To compare the diagnostic accuracy and interrater agreement of multiparametric MRI and 68Ga-PSMA-11 PET/MRI for 
the detection of extracapsular extension (ECE) and seminal vesicle infiltration (SVI) in patients with prostate cancer.
Materials and Methods: Retrospective analysis of 40 consecutive men who underwent multiparametric MRI and 68Ga-PSMA-11 PET/
MRI within 6 months for suspected prostate cancer followed by radical prostatectomy between April 2016 and July 2018. Four 
readers blinded to clinical and histopathologic findings rated the probability of ECE and SVI at multiparametric MRI and PET/
MRI by using a five-point Likert-type scale. The prostatectomy specimen served as the reference standard. Accuracy was assessed 
with a multireader multicase analysis and by calculating reader-average areas under the receiver operating characteristics curve 
(AUCs), sensitivity, and specificity for ordinal and dichotomized data in a region-specific and patient-specific approach. Interrater 
agreement was assessed with the Fleiss multirater k.
Results: For multiparametric MRI versus PET/MRI in ECE detection, respectively, AUC, sensitivity, and specificity in the region-
specific analysis were 0.67 and 0.75 (P = .07), 28% (21 of 76) and 47% (36 of 76) (P = .09), and 94% (529 of 564) and 90% (509 
of 564) (P = .007). For the patient-specific analysis, AUC, sensitivity, and specificity were 0.66 and 0.73 (P = .19), 46% (22 of 48) 
and 69% (33 of 48) (P = .04), and 75% (84 of 112) and 67% (75 of 112) (P = .19), respectively. For multiparametric MRI versus 
PET/MRI in SVI detection, respectively, AUC, sensitivity, and specificity of the region-specific analysis were 0.66 and 0.74 (P = 
.21), 35% (seven of 20) and 50% (10 of 20) (P = .25), and 98% (295 of 300) and 94% (282 of 300) (P , .001). For the patient-
specific analysis, AUC, sensitivity, and specificity were 0.65 and 0.79 (P = .25), 35% (seven of 20) and 55% (11 of 20) (P = .20), 
and 98% (137 of 140) and 94% (131 of 140) (P = .07), respectively. Interrater reliability for multiparametric MRI versus PET/
MRI did not differ for ECE (k, 0.46 vs 0.40; P = .24) and SVI (k, 0.23 vs 0.33; P = .39).
Conclusion: Our results suggest that gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC ligand targeting the prostate-specific 
membrane antigen (PSMA) (68Ga-PSMA-11) PET/MRI and multiparametric MRI perform similarly for local staging of prostate 
cancer in patients with intermediate-to-high-risk prostate cancer. The increased sensitivity of 68Ga-PSMA-11 PET/MRI for the de-
tection of extracapsular disease comes at the cost of a slightly reduced specificity.
© RSNA, 2019
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Study inclusion criteria were as follows: (a) multiparametric 
MRI within 6 months from PET/MRI and (b) subsequent RP 
at our institution (within 6 months of imaging). Patients were 
excluded if the multiparametric MRI study was not performed 
according to current guidelines (20). Risk classification was de-
termined according to the D’Amico classification (21).
Multiparametric MRI Data
MRI was performed with a 1.5-T (10% [four of 40]) or a 
3.0-T (90% [36 of 40]) whole-body MRI system at different 
institutions (n = 29 in house, n = 11 externally performed). The 
protocol was in accordance with proposed technical require-
ments of current guidelines (20). At our institution, the typical 
multiparametric MRI protocol consisted of T2-weighted fast 
spin-echo images covering the prostate gland and the seminal 
vesicles, which were obtained in three planes (transverse, sagit-
tal, and coronal). Diffusion-weighted imaging was performed 
in the transverse plane with identical orientation as the T2-
weighted images. The apparent diffusion coefficient parametric 
maps were calculated by using three b values (0, 50, and 1000 
sec/mm2 or 100, 600, and 1000 sec/mm2). A high–b-value im-
age (1400 sec/mm2) was calculated. Dynamic contrast material– 
enhanced MRI was performed to yield transverse sections 
with a temporal resolution of less than 8 seconds. Gadoter-
ate meglumine (Dotarem; Guerbet, Darmstadt, Germany) was 
used as a contrast agent in a dose of 0.1 mmol per kilogram of 
body weight. The typical MRI protocol included T2-weighted 
images in three planes, diffusion-weighted imaging, and dy-
namic contrast-enhanced imaging.
Data Acquisition with 68Ga-PSMA-11 PET/MRI
All PET/MRI data were acquired with a 3.0-T hybrid scanner 
(SIGNA PET/MR; GE Healthcare, Waukesha, Wis) at our in-
stitution. The spatial resolution (full width at half maximum) for 
68Ga was 5.46, 5.26, and 6.10 mm (in the x, y, and z directions, 
respectively) in air and 5.63, 4.77, and 6.47 mm (in the x, y, 
and z direction, respectively) in water (22). Patients underwent 
68Ga-PSMA-11 PET/MRI 60 minutes after a single injection 
of 68Ga-PSMA-11 (mean dose, 131 MBq 6 18.8 [standard de-
viation]; range, 98–158 MBq). To reduce tracer activity in the 
bladder, furosemide (0.13 mg/kg) was injected intravenously 
30 minutes prior to the tracer injection, and patients were 
asked to void prior to scanning. The institutional PET proto-
col was in agreement with the European Association of Nuclear 
Medicine and Society of Nuclear Medicine and Molecular Im-
aging procedure guidelines (23). In brief, the protocol consists 
of six bed positions with 2–3 minutes acquisition time per bed 
position for the head to mid-thigh protocol and additional 
specific sequences covering the pelvis, including a high-reso-
lution T1-weighted LAVA-FLEX sequence (GE Healthcare, 
Waukesha, Wis), a T2-weighted fast recovery fast spin-echo se-
quence in at least two planes, and diffusion-weighted imaging. 
Three-dimensional PET emission data were reconstructed by 
using time-of-flight information and a fully three-dimensional 
iterative algorithm, which is part of the manufacturer-supplied 
standard scanner software (ordered subset expectation maxi-
mization–based VUE Point FX; GE Healthcare). The recon-
Abbreviations
AUC = area under the ROC curve, CI = confidence interval, ECE = 
extracapsular extension, MRMC = multireader multicase, PSMA = 
prostate-specific membrane antigen, ROC = receiver operating charac-
teristic, RP = radical prostatectomy, SVI = seminal vesicle infiltration
Summary
While overall diagnostic performance in local staging of patients 
with prostate cancer at intermediate to high risk was similar, use of 
a gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC ligand 
targeting the prostate-specific membrane antigen (PSMA) (68Ga-
PSMA-11) PET/MRI may improve the sensitivity of multiparametric 
MRI for the detection of extracapsular disease, at the cost of a slightly 
reduced specificity.
Key Results
 n Patient-specific sensitivity for the detection of extracapsular exten-
sion of prostate cancer was higher for gallium 68 (68Ga)-labeled 
Glu-urea-Lys (Ahx)-HBED-CC ligand targeting the prostate-spe-
cific membrane antigen (PSMA) (68Ga-PSMA-11) PET/MRI than 
for multiparametric MRI (69% vs 46%, respectively; P = .04.)
 n Region-specific specificity for the detection of extracapsular exten-
sion and seminal vesicle infiltration was lower for 68Ga-PSMA-11 
PET/MRI than for multiparametric MRI (90% vs 94%, P = .007 
and 94% vs 98%, P , .001, respectively).
 n There was no difference in the interrater agreement of extracapsu-
lar extension and seminal vesicle infiltration estimation between 
multiparametric MRI and 68Ga-PSMA-11 PET/MRI (Fleiss k, 
0.46 vs 0.40, P = .24 and 0.23 vs 0.33, P = .39, respectively).
Gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC 
ligand targeting the prostate-specific membrane antigen (PSMA) 
(68Ga-PSMA-11) PET is an upcoming imaging modality. It is 
especially beneficial in the setting of biochemical recurrence of 
prostate cancer after local treatment. This is mainly because of 
its superior detection rate compared with conventional imaging 
and with previously established radiotracers such as radiolabeled 
choline (12–14).
Recent studies reported additive value of combined 68Ga-
PSMA-11 PET and MRI for primary prostate cancer detection 
(15–17), local recurrence detection after focal therapy (18), and 
localization (19) compared with multiparametric MRI.
To our knowledge, the potential benefit of 68Ga-PSMA-11 
PET/MRI for local staging in patients with intermediate-to-
high–risk prostate cancer has not yet been investigated and 
compared with that of multiparametric MRI. Therefore, the 
objective of our study was to compare the diagnostic accuracy 
and interrater agreement of multiparametric MRI and 68Ga-
PSMA-11 PET/MRI for the detection of ECE and SVI in pa-
tients with prostate cancer.
Materials and Methods
The institutional review board approved this single-center ret-
rospective study, and written informed consent was obtained 
from all participants.
Patients
We reviewed all consecutive patients undergoing 68Ga-
PSMA-11 PET/MRI for primary staging of prostate cancer (n = 
103) over a 2-year period (April 2016 through July 2018). 
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struction included standard 
scatter, dead-time, random at-
tenuation, and normalization 
correction, as well as correction 
for the detector response by us-
ing Sharper (GE Healthcare). 
All reconstructions were post-
filtered in image space by using 
an in-plane Gaussian convolu-
tion kernel with a full width at 
half-maximum of 5.0 mm, fol-
lowed by a standard axial filter 
with a 3-second kernel using 
relative weights of 1:4:1. The 
reconstruction diameter was 
60 cm, and the image grid was 
256 3 256 with 2.34 3 2.34 
3 2.78 mm3 voxels.
Image Analysis
Four board-certified radiologists 
(C.S.R. [reviewer 1], A.M.H. 
[reviewer 2], K.S. [reviewer 3], 
and A.S.B. [reviewer 4]) with 
7 years, 5 years, 1 year, and 1 
year of experience in urogenital 
Table 1: Summary of Characteristics in 40 Patients
Characteristic Datum
Age (y)* 63 6 6
PSA level (ng/mL)† 8.12 (7.56)
Gleason score at biopsy
 3 + 4 2 (5)
 4 + 3 6 (15)
 4 + 4 21 (52.5)
 4 + 5 10 (25)
 5 + 4 1 (2.5)
Risk according to D’Amico classification
 Intermediate 8 (20)
 High 32 (80)
Tumor stage
 pT2a 2 (5)
 pT2b 1 (2.5)
 pT2c 24 (60)
 pT3a 8 (20)
 pT3b 5 (12.5)
Time between multiparametric MRI and  
  68Ga-PSMA-11 PET/MRI (mo)*
3 6 2
Time between last imaging and operation (mo)* 1 6 1
Note.—Unless otherwise specified, data are numbers of patients, 
with percentages in parentheses. 68Ga-PSMA-11 = gallium 
68–labeled 68Ga-labeled (Glu-urea-Lys (Ahx)-HBED-CC) 
ligand targeting the prostate-specific membrane antigen, PSA = 
prostate-specific antigen.
* Data are means 6 standard deviations.
† Data are medians, with interquartile ranges in parentheses.
Figure 1: Patient flowchart. MP = multiparametric, PSMA-11 = gallium 68–
labeled (Glu-urea-Lys (Ahx)-HBED-CC) ligand targeting the prostate-specific 
membrane antigen.
Table 2: Reader-Average Diagnostic Accuracy of Multiparametric MRI and 68Ga-PSMA-11 
PET/MRI for the Detection of ECE and SVI
Parameter Multiparametric MRI 68Ga-PSMA-11 PET/MRI P Value
Region-specific ECE
 AUC 0.67 (0.6, 0.73) 0.75 (0.63, 0.87) .07
 Sensitivity (%) 28 (10, 45) [21/76] 47 (23, 71) [36/76] .09
 Specificity (%) 94 (90, 98) [529/564] 90 (86, 94) [509/564] .007
Patient-specific ECE
 AUC 0.66 (0.65, 0.67) 0.73 (0.72, 0.73) .19
 Sensitivity (%) 46 (42, 50) [22/48] 69 (67, 70) [33/48] .04
 Specificity (%) 75 (74, 76) [84/112] 67 (66, 68) [75/112] .19
Region-specific SVI
 AUC 0.66 (0.44, 0.88) 0.74 (0.6, 0.88) .21
 Sensitivity (%) 35 (28, 78) [7/20] 50 (19, 81) [10/20] .25
 Specificity (%) 98 (96, 100) [295/300] 94 (90, 98) [282/300] ,.001
Patient-specific SVI
 AUC 0.65 (0.62, 0.68) 0.79 (0.78, 0.81) .25
 Sensitivity (%) 35 (26, 44) [7/20] 55 (51, 59) [11/20] .20
 Specificity (%) 98 (98, 98) [137/140] 94 (93, 94) [131/140] .07
Note.—Data in parentheses are 95% confidence intervals; data in brackets are raw data. AUC 
= area under the receiver operating characteristic curve, ECE = extracapsular extension, 68Ga-
PSMA-11 = gallium 68–labeled (Glu-urea-Lys (Ahx)-HBED-CC) ligand targeting the prostate-
specific membrane antigen,  
SVI = seminal vesicle invasion.
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tensity and/or abnormal contrast material enhancement within 
and/or along the seminal vesicle, restricted diffusion, oblitera-
tion of the angle between the base of the prostate and the semi-
nal vesicle, and demonstration of direct tumor extension from 
the base of the prostate into or around the seminal vesicle). For 
PET/MRI, identical features, with the addition of pathologic 
68Ga-PSMA-11 accumulation (ie, tracer uptake exceeding that 
of background tissue) outside of the prostate and within and/or 
along the seminal vesicle were used.
Anonymized and randomly ordered image studies were re-
viewed independently in two sessions in this order: (a) multipa-
rametric MRI on a standard picture archiving and communica-
tion system workstation (AGFA Healthcare, Mortsel, Belgium) 
and (b) PET/MRI on a standard workstation (Advantage Work-
station, version 4.6; GE Healthcare). All readers were blinded to 
clinical and histopathologic findings. An interval of more than 
radiology and 6 years, 1 year, 1 year, and 1 year of experience in 
hybrid imaging, respectively, rated the probability of (a) ECE 
in four regions (anterior/posterior part of the prostate on right/
left side) and (b) SVI in two regions (right/left side) on images 
from multiparametric MRI and PET/MRI by using a five-point 
Likert-type scale (where 1 = absent, 2 = probably absent, 3 = 
equivocal, 4 = probably present, and 5 = definitively present). 
Estimations of the probability of ECE/SVI were subjective and 
guided by features of the Prostate Imaging Reporting and Data 
System, or PI-RADS, version 2 (20) for multiparametric MRI 
(ie, for ECE invasion or asymmetry of the neurovascular bun-
dles, an irregular or spiculated prostatic margin, a bulging pros-
tatic contour, obliteration of the rectoprostatic angle, a tumor-
capsule interface of greater than 1.0 cm, breakthrough of the 
capsule with evidence of direct tumor extension or bladder wall 
invasion and SVI, focal or diffuse low T2-weighted signal in-




Multiparametric MRI 68Ga-PSMA-11 PET/MRI Multiparametric MRI 68Ga-PSMA-11 PET/MRI
Region specific
 AUC
  Reader 1 0.65 (0.64, 0.65) 0.74 (0.74, 0.75) 0.69 (0.66, 0.72) 0.77 (0.74, 0.8)
  Reader 2 0.67 (0.66, 0.68) 0.71 (0.7, 0.72) 0.70 (0.67, 0.72) 0.67 (0.64, 0.7)
  Reader 3 0.70 (0.69, 0.7) 0.77 (0.77, 0.78) 0.57 (0.54, 0.6) 0.76 (0.73, 0.79)
  Reader 4 0.65 (0.64, 0.66) 0.78 (0.77, 0.79) 0.68 (0.65, 0.71) 0.77 (0.74, 0.8)
 Sensitivity (%)
  Reader 1 26 (24, 28) [5/19] 32 (30, 33) [6/19] 40 (28, 52) [2/5] 40 (28, 52) [2/5]
  Reader 2 16 (12, 20) [3/19] 37 (34, 39) [7/19] 40 (32, 48) [2/5] 40 (28, 52) [2/5]
  Reader 3 32 (30, 34) [6/19] 53 (51, 54) [10/19] 20 (8, 32) [1/5] 60 (48, 72) [3/5]
  Reader 4 37 (32, 42) [7/19] 68 (65, 72) [13/19] 40 (28, 52) [2/5] 60 (48, 72) [3/5]
 Specificity (%)
  Reader 1 94 (94, 94) [132/141] 92 (92, 92) [130/141] 100 (100, 100) [75/75] 96 (96, 96) [72/75]
  Reader 2 97 (97, 97) [137/141] 93 (93, 93) [131/141] 100 (100, 100) [75/75] 96 (96, 96) [72/75]
  Reader 3 94 (94, 94) [133/141] 89 (89, 89) [126/141] 97 (97, 97) [73/75] 92 (92, 92) [69/75]
  Reader 4 90 (90, 90) [127/141] 87 (86, 87) [122/141] 96 (96, 96) [72/75] 92 (92, 92) [69/75]
Patient specific
 AUC
  Reader 1 0.66 (0.64, 0.68) 0.7 (0.68, 0.71) 0.67 (0.64, 0.71) 0.87 (0.85, 0.89)
  Reader 2 0.62 (0.6, 0.64) 0.69 (0.68, 0.71) 0.69 (0.66, 0.72) 0.77 (0.74, 0.8)
  Reader 3 0.68 (0.67, 0.7) 0.76 (0.75, 0.78) 0.56 (0.54, 0.59) 0.77 (0.73, 0.8)
  Reader 4 0.69 (0.68, 0.71) 0.75 (0.74, 0.76) 0.67 (0.64, 0.7) 0.76 (0.73, 0.79)
 Sensitivity (%)
  Reader 1 42 (37, 46) [5/12] 58 (54, 63) [7/12] 40 (28, 52) [2/5] 60 (48, 72) [3/5]
  Reader 2 25 (22, 28) [3/12] 58 (54, 63) [7/12] 40 (28, 52) [2/5] 40 (28, 52) [2/5]
  Reader 3 42 (37, 46) [5/12] 67 (63, 71) [8/12] 20 (12, 28) [1/5] 60 (48, 72) [3/5]
  Reader 4 75 (72, 78) [9/12] 92 (90, 93) [11/12] 40 (28, 52) [2/5] 60 (48, 72) [3/5]
 Specificity (%)
  Reader 1 75 (74, 76) [21/28] 75 (74, 76) [21/28] 100 (100, 100) [35/35] 94 (94, 95) [33/35]
  Reader 2 86 (85, 87) [24/28] 68 (66, 69) [19/28] 100 (100, 100) [35/35] 97 (97, 97) [34/35]
  Reader 3 75 (74, 76) [21/28] 68 (66, 69) [19/28] 97 (97, 97) [34/35] 91 (91, 92) [32/35]
  Reader 4 64 (63, 66) [18/28] 57 (55, 59) [16/28] 94 (94, 95) [33/35] 91 (91, 92) [32/35]
Note.—Data in parentheses are 95% confidence intervals; data in brackets are raw data. AUC = area under the receiver operating charac-
teristic curve, ECE = extracapsular extension, 68Ga-PSMA-11 = gallium 68–labeled (Glu-urea-Lys (Ahx)-HBED-CC) ligand targeting the 
prostate-specific membrane antigen, SVI = seminal vesicle invasion.
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(Likert scale points were dichotomized as  3 = negative vs . 
3 = positive) for region-specific and patient-specific ECE and 
SVI detection. For the region-specific approach, any region with 
3 weeks between the reading sessions 
was maintained to avoid recall bias.
Reference Standard
Pathologic stage at RP was used as 
the reference standard for ECE and 
SVI. Histologic findings in all cases 
were reevaluated by two experienced 
genitourinary pathologists (N.J.R., 
J.H.R.) unblinded to clinical infor-
mation and blinded to all imaging 
results, using a standard protocol. 
Mutual agreement for extraprostatic 
extension was achieved. All regions 
showing histologic extraprostatic 
extension (according to the Interna-
tional Society of Urological Pathol-
ogy consensus conference), including 
SVI, were documented individually.
Statistical Analysis
All statistical analyses were performed 
in R (version 3.5.1; R Foundation for 
Statistical Computing, Vienna, Aus-
tria. https://www.R-project.org/). Pa-
tient demographics and baseline clini-
cal characteristics were summarized by 
using descriptive statistics. Frequency 
distribution with percentages was used 
to summarize categorical variables, 
and means with standard deviations or 
medians with interquartile ranges were 
used to describe continuous variables. 
Diagnostic accuracy for detection of 
ECE and SVI was analyzed in four dif-
ferent approaches for each reader and 
modality. Likert scale points were used 
for receiver operating characteristics 
(ROC) analysis and calculation of the 
area under the ROC curve (AUC) for 
region-specific detection. The highest 
Likert scale point per patient was determined for ROC analy-
sis and calculation of the AUC for patient-specific detection. 
Sensitivity and specificity were calculated on dichotomized data 
Figure 2: Graphs show the average receiver operating char-
acteristic (ROC) curves of four readers for multiparametric (MP) 
MRI (blue curve) and gallium 68 (68Ga)-labeled Glu-urea-Lys 
(Ahx)-HBED-CC ligand targeting the prostate-specific membrane 
antigen (68Ga-PSMA-11) PET/MRI (green curve) for the region-
specific detection of (a) extracapsular extension (area under the 
ROC curve [AUC], 0.67 [95% confidence interval {CI}: 0.6, 0.73] 
and 0.75 [95% CI: 0.63, 0.8], P = .07, respectively) and (b) semi-
nal vesicle infiltration (AUC, 0.66 [95% CI: 0.44, 0.88] and 0.74 
[95% CI: 0.6, 0.88], P = .21, respectively) of prostate cancer.
Figure 3: Bar graphs show sensitivity and specificity of multiparametric (MP) MRI (blue) compared with gallium 
68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC ligand targeting the prostate-specific membrane antigen (68Ga-
PSMA-11) PET/MRI (green) for four readers (R1, R2, R3, R4), and reader-average sensitivity and specificity values 
(Av. R1-R4) for the patient-specific detection of (a) extracapsular extension and (b) seminal vesicle infiltration.
Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Prostate Cancer
6 radiology.rsna.org n Radiology: Volume 00: Number 0— 2019
Figure 4: A–D, Images from axial multiparametric MRI and, E–G, corresponding images from gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC ligand target-
ing the prostate-specific membrane antigen (68Ga-PSMA-11) PET/MRI in a 65-year-old man with a prostate-specific antigen level of 4.2 ng/mL. A, T2-weighted image, 
B, dynamic contrast-enhanced image, C, diffusion-weighted image (b = 1400 sec/mm2) and, D, corresponding apparent diffusion coefficient map show low T2 signal in-
tensity in the left posterior peripheral zone (arrow) with corresponding restricted diffusion. E, T2-weighted image, F, PET image (standardized uptake value range, 0–8) and, 
G, fused PET/MRI image show focal radiotracer uptake in the left posterior peripheral zone on the left (arrow). One of four readers rated the images from multiparametric 
MRI as positive for extraprostatic extension, whereas three of four readers rated the images from PET/MRI positive for extraprostatic extension. H, Histopathologic slide of 
the basal posterior left prostate confirms the presence of tumor with extraprostatic extension (arrow), including extension beyond the prostatic contour and infiltration into fat 
tissue. (Hematoxylin-eosin stain; scale bar = 5 mm.)
Figure 5: A–D, Images from axial multiparametric MRI and, E–G, corresponding images from gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC ligand target-
ing the prostate-specific membrane antigen (68Ga-PSMA-11) PET/MRI in a 72-year-old man with a prostate-specific antigen level of 26.5 ng/mL. A, T2-weighted image, 
B, dynamic contrast-enhanced image, C, diffusion-weighted image (b = 1400 sec/mm2), and, D, corresponding apparent diffusion coefficient map show low T2 signal 
intensity in the left posterior peripheral zone (arrow) with corresponding restricted diffusion. E, T2-weighted image, F, PET image (standardized uptake value range, 0–8) 
and, G, fused PET/MRI image show focal radiotracer uptake in the left posterior peripheral zone on the left (arrow). Three of four readers rated the multiparametric MRI as 
negative for extraprostatic extension, whereas all rated the PET/MRI positive for extraprostatic extension. H, Histopathologic slide of midprostate confirms a small focus of 
prostate carcinoma in the left posterior peripheral zone (arrow) without extraprostatic extension. (Hematoxylin-eosin stain; scale bar = 5 mm.)
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ECE/SVI identified at histopathologic examination that corre-
sponded to the same region with tumor graded as positive at im-
aging was considered as a true-positive finding, whereas regions 
negative for tumor at pathologic examination with correspond-
ing regions graded as negative for tumor at imaging were consid-
ered as true-negative findings. For the patient-specific approach, 
all patients with at least one positive region were considered as 
positive for disease and all patients with no positive regions were 
considered as negative for disease.
To calculate reader-average AUC, sensitivity, and specific-
ity, as well as to compare these estimates between multipara-
metric MRI and PET/MRI, a multireader multicase (MRMC) 
approach including U statistics was used (24,25). To account for 
the correlation of the clustered data (ie, multiple measurement 
within each patient) the method proposed by Obuchowski was 
applied (26). Interrater reliability was calculated with the Fleiss 
multirater k and compared by using the Hotelling T2 test (27). 
Two-sided P values of less than .05 were considered to indicate 
statistically significant differences.
Results
Patient characteristics are summarized in Table 1. Figure 1 
shows the patient flowchart. Forty patients were eligible for 
our study. The mean age of the patients was 63 years (range, 
51–78 years). Eighty percent (32 of 40) of the patients had a 
high-risk setting, and 20% (eight of 40) had an intermediate-
risk setting according to the D’Amico classification. Histologic 
examination revealed 8.5% (19 of 160) of the regions as posi-
tive for ECE in 30% (12 of 40) of the patients and 6.3% (five 
of 80) of the regions as positive for SVI in 12.5% (five of 40) 
of the patients.
Diagnostic Accuracy for the Detection of ECE
For multiparametric MRI versus PET/MRI, respectively, 
the region-specific MRMC analysis results were as follows: 
AUC, 0.67 (95% confidence interval [CI]: 0.6, 0.73) and 
0.75 (95% CI: 0.63, 0.87), P = .08; sensitivity, 28% (21 of 
76) (95% CI: 1%, 45%) and 47% (36 of 76) (95% CI: 23%, 
71%), P = .09; and specificity, 94% (529 of 564) (95% CI: 
90%, 98%) and 90% (509 of 564) (95% CI: 86%, 94%), 
P = .007. Reader-specific AUC ranged from 0.65 to 0.70 
for multiparametric MRI and from 0.71 to 0.78 for PET/
MRI. Table 2 summarizes reader-average accuracy results, 
and Table 3 summarizes reader-specific accuracy results. 
Reader-average ROC curves of the region-specific analysis 
of the readers are illustrated in Figure 2, indicating higher 
AUCs for PET/MRI.
For multiparametric MRI versus PET/MRI, respectively, 
the patient-specific MRMC analysis results were as follows: 
AUC, 0.66 (95% CI: 0.65, 0.67) and 0.73 (95% CI: 0.72, 
0.73), P = .19; sensitivity, 46% (22 of 48) (95% CI: 42%, 
50%) and 69% (33 of 48) (95% CI: 67%, 70%), P = .04; 
and specificity, 75% (84 of 112) (95% CI: 74%, 76%) and 
67% (75 of 112) (95% CI: 66%, 68%), P = .19. Figure 3a il-
lustrates the differences in sensitivities and specificities between 
multiparametric MRI and PET/MRI for the patient-specific 
Figure 6:  A–D, Axial multiparametric MRIs and, E–G, corresponding images from gallium 68 (68Ga)-labeled Glu-urea-Lys (Ahx)-HBED-CC ligand targeting the pros-
tate-specific membrane antigen (68Ga-PSMA-11) PET/MRI in a 62-year-old man with a prostate-specific antigen level of 12.83 ng/mL. Full image correlation is limited 
due to differences in the filling of the urinary bladder. A, T2-weighted image, B, dynamic contrast-enhanced image, C, diffusion-weighted image (b = 1400 sec/mm2), and, 
D, corresponding apparent diffusion coefficient map show unremarkable right seminal vesicle. E, T2-weighted image, F, PET image (standardized uptake value range, 0–8) 
and, G, fused PET/MRI image show focal 68Ga-PSMA-11 uptake in the right seminal vesicle (arrow). All four readers rated the multiparametric MRI as negative for seminal 
vesicle invasion, whereas three of four readers rated the PET/MRI positive for seminal vesicle infiltration on the right. H, Histopathologic slide of the base of the prostate and 
right seminal vesicle confirms presence of tumor in the right peripheral zone (arrow) without seminal vesicle infiltration on the right side. (Hematoxylin-eosin stain; scale bar = 5 mm.)
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approach and shows that all four readers achieved higher sen-
sitivity with PET/MRI. Figures 4 and 5 show examples of dis-
cordant multiparametric MRI and PET/MRI findings; while 
Figure 4 depicts a case with a majority of false-negative ECE 
multiparametric MRI image interpretations (three of four 
readers), Figure 5 shows a case with false-positive ECE PET/
MRI image interpretations for all readers.
Diagnostic Accuracy for the Detection of SVI
For multiparametric MRI versus PET/MRI, respectively, the 
region-specific MRMC analysis results were as follows: AUC, 
0.66 (95% CI: 0.44, 0.88) and 0.74 (95% CI: 0.6, 0.88), P = 
.21; sensitivity, 35% (seven of 20) (95% CI: –8%, 78%) and 
50% (10 of 20) (95% CI: 19%, 81%), P = .25; and specificity, 
98% (295 of 300) (95% CI: 96%, 100%) and 94% (282 of 
300) (95% CI: 90%, 98%), P , .001. Reader-specific AUC 
ranged from 0.57 to 0.70 for multiparametric MRI and from 
0.67 to 0.77 for PET/MRI. Figure 3b illustrates the differences 
in sensitivities and specificities between multiparametric MRI 
and PET/MRI for the patient-specific approach and shows 
that all readers achieved a slightly lower specificity in the detec-
tion of SVI with PET/MRI. Table 2 summarizes reader-average 
accuracy results, and Table 3 summarizes reader-specific accu-
racy results.
For multiparametric MRI versus PET/MRI, respectively, the 
patient-specific MRMC analysis results were as follows: AUC, 
0.65 (95% CI: 0.62, 0.68) and 0.79 (95% CI: 0.78, 0.81), 
P = .25; sensitivity, 35% (seven of 20) (95% CI: 26%, 44%) and 
55% (11 of 20) (95% CI: 51%, 59%), P = .20; and specificity, 
98% (137 of 140) (95% CI: 98%, 98%) and 95% (131 of 140) 
(95% CI: 93%, 94%), P = .07. Figure 6 shows an example of 
discordant multiparametric MRI and PET/MRI findings with a 
majority of false-positive SVI PET/MRI image interpretations 
(three of four readers).
Interrater Reliability
The Fleiss k for the rating of the probability of ECE was 0.46 
(95% CI: 0.36, 0.55) for multiparametric MRI and 0.40 (95% 
CI: 0.33, 0.47) for PET/MRI, P = .24. The Fleiss k for the rat-
ing of the probability of SVI was 0.23 (95% CI: 0.10, 0.46) 
for multiparametric MRI and 0.33 (95% CI: 0.17, 0.25) for 
PET/MRI, P = .39.
Discussion
The potential benefit of gallium 68 (68Ga)-labeled Glu-urea-
Lys (Ahx)-HBED-CC ligand targeting the prostate-specific 
membrane antigen (PSMA) (68Ga-PSMA-11) PET/MRI for 
local staging in patients with intermediate-to-high–risk pros-
tate cancer has not yet been investigated and compared with 
multiparametric MRI. In our study, including 40 patients 
with intermediate-to-high–risk prostate cancer undergoing 
multiparametric MRI and 68Ga-PSMA-11 PET/MRI before 
RP, we found that 68Ga-PSMA-11 PET/MRI increased the 
sensitivity for the detection of ECE of prostate cancer (69% 
[33 of 48] vs 46% [22 of 48], respectively; P = .04) with a 
slight reduction in specificity (90% [509 of 564] vs 94% [529 
of 564], respectively; P = .007) compared with multiparamet-
ric MRI. Moreover, we found a slight reduction in specificity 
(94% [282 of 300] vs 98% [295 of 300], respectively; P 
, .001) for the detection of SVI with 68Ga-PSMA-11 PET/
MRI compared with multiparametric MRI. However, in the 
region-specific analysis, we did not find a difference in sensi-
tivity for the detection of ECE and SVI with 68Ga-PSMA-11 
PET/MRI. On the other hand, specificity in detection of 
ECE and SVI was higher with multiparametric MRI than 
with 68Ga-PSMA-11 PET/MRI.
Combining the functional information from 68Ga-PSMA-11 
PET with the well-established technique of multiparametric 
MRI might explain the higher sensitivity for the detection of lo-
cally advanced disease. Previous studies reported improved sen-
sitivity for primary prostate cancer detection for 68Ga-PSMA-11 
PET/MRI compared with multiparametric MRI (15,16), which 
might allow the reader to focus on locally advanced disease in 
the regions suspected of harboring primary prostate cancer. One 
reason the rather small differences in specificity of region-specific 
ECE and SVI were statistically significant and the rather large 
differences in sensitivity were not may be because specificity 
was based on many (eg, for ECE, n = 141) true-negative events 
and sensitivity was based on rather few true-positive events (eg, 
for ECE, n = 19), which is an inherent limitation of the sam-
ple distribution in our cohort. Several factors leading to false-
positive findings could explain the slightly lower specificity of 
68Ga-PSMA-11 PET/MRI (28). Moreover, high accumulation 
of 68Ga-PSMA-11 in aggressive tumors can lead to spillover of 
activity into normal tissue, as has previously been described in 
choline PET/CT for local staging of prostate cancer (29). Spatial 
resolution of T2-weighted images is essential for adequate lo-
cal staging (20). Therefore, differences in signal-to-noise ratio or 
spatial resolution of the images from PET/MRI and MRI may 
also play an important role in the evaluation of locally advanced 
disease in patients with prostate cancer.
Current studies investigating the diagnostic accuracy of mul-
tiparametric MRI for the detection of ECE using a comparable 
imaging protocol showed similar accuracy compared with our 
study results. Mehralivand et al (30) reported an AUC of 0.77 
for the detection of extraprostatic extension in a cohort of 553 
patients using a newly introduced grading system for extrapros-
tatic extension. Krishna et al (31) reported a sensitivity of 43% 
and a specificity of 91.3% and an AUC of 0.67 for the detection 
of ECE in a cohort of 149 patients. The higher sensitivity of 
66% for the detection of SVI reported by Soylu et al (32) may in 
part be explained by the use of an endorectal coil in their cohort, 
which was paralleled by a substantial increase in signal-to-noise 
ratio (21).
Only a few studies have investigated the diagnostic accuracy 
of PSMA PET for the detection of ECE and SVI. Thalgott et al 
(33) reported comparable AUCs of 0.70 for ECE and 0.81 for 
SVI using 68Ga PSMA-11 PET/MRI in a cohort of 73 patients. 
Fendler et al (34) reported similar values of sensitivity and speci-
ficity for ECE and SVI detection. von Klot et al (35) reported 
a higher sensitivity of 90% and a similar specificity of 91% for 
the detection of ECE and similar values (75% and 100%) for 
the detection of SVI using 68Ga PSMA-I&T PET/CT in a small 
cohort of 21 patients.
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The main limitations of our study were the small sample 
size, which was partially mitigated by MRMC analysis, and 
its retrospective nature, which entails a selection bias. Our re-
sults apply to a selected group of patients with intermediate-to-
high–risk prostate cancer who are therefore more likely to over-
express PSMA and have a higher T-stage at presentation. The 
results from our study may therefore not apply to populations 
including patients with low-risk prostate cancer. However, 
68Ga-PSMA-11 PET/MRI is usually performed in patients 
with higher-risk prostate cancer for exclusion of distant disease. 
Because of time constraints during the PET/MRI examination, 
our PET/MRI protocol did not include a dynamic contrast-
enhanced sequence, which might have limited the accuracy of 
SVI detection. In addition, the parameters for multiparamet-
ric MRI were not homogeneous (n = 11 multiparametric MRI 
studies were acquired at external institutions).
In conclusion, our results suggest that gallium 68 (68Ga)-la-
beled Glu-urea-Lys (Ahx)-HBED-CC ligand targeting the pros-
tate-specific membrane antigen (PSMA) (68Ga-PSMA-11) 
PET/MRI and multiparametric MRI perform similarly in local 
staging of prostate cancer in patients with intermediate-to-high–
risk prostate cancer. The increased sensitivity of 68Ga-PSMA-11 
PET/MRI for the detection of extracapsular disease comes at the 
cost of a slightly reduced specificity.
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